Infliximab
- Generic Name
- Infliximab
- Brand Names
- Avsola, Flixabi, Inflectra, Remicade, Renflexis, Zessly, Remsima
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 170277-31-3
- Unique Ingredient Identifier
- B72HH48FLU
- Background
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammato...
- Indication
用于治疗：
⑴类风湿性关节炎：本品常与甲氨蝶呤合用于中重度活动性类风湿性关节炎；
⑵克罗恩病及瘘管性克罗恩病；
⑶强直性脊柱炎等自身免疫性疾病，以减轻症状和体征，改善身体机能，预防患者残疾。
⑷用于银屑病关节炎的治疗【美国FDA已批准；英国风湿病学会/英国风湿病卫生专业人员协会《BSR／BHPR—应用生物制剂治疗银屑病关节炎指南》2012版；欧洲抗风湿病联盟《EULAR—银屑病关节炎药 物治疗管理建议》2011版
】。
⑸用于6岁及以上儿童溃疡性结肠炎的治疗【美国FDA已批准；中华医学会内科学会《炎症性肠病诊断与治疗的共识意见》；中华医学会消化病学分会炎症性肠病学组《英夫利西治疗克罗恩病的推荐方案（2011年】。
- Associated Conditions
- Ankylosing Spondylitis (AS), Chronic Plaque Psoriasis, Fistulizing Crohn's Disease, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Pediatric Crohn’s Disease, Psoriatic Arthritis
- Associated Therapies
- -
Treatment of Perianal Crohn's Disease, Combining Medical and Surgical Treatment.
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-04-24
- Lead Sponsor
- Sheba Medical Center
- Registration Number
- NCT00252369
- Locations
- 🇮🇱
Meir Medical Center, Kfar Saba, Israel
🇮🇱Tel Aviv Medical Center, Tel Aviv, Israel
🇮🇱Sheba Medical Center, Tel Hashomer, Israel
The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 868
- Registration Number
- NCT00251641
The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol
- Conditions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Centocor Ortho Biotech Services, L.L.C.
- Target Recruit Count
- 210
- Registration Number
- NCT00246064
New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis
- Conditions
- First Posted Date
- 2005-10-26
- Last Posted Date
- 2006-09-08
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 40
- Registration Number
- NCT00244179
- Locations
- 🇩🇪
Charite Campus Benjamin Franklin, Rheumatology, Berlin, Germany
A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 607
- Registration Number
- NCT00236028
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2008-06-03
- Lead Sponsor
- Rheumazentrum Ruhrgebiet
- Target Recruit Count
- 149
- Registration Number
- NCT00237419
- Locations
- 🇳🇱
Academic Ziekenhuis, Amsterdam, Netherlands
🇧🇪Erasme University Hospital, Brussels, Belgium
🇫🇷Groupe Hopitalier Cochin, Paris, France
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis
- Conditions
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2011-06-09
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 249
- Registration Number
- NCT00230529
GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- Emory University
- Registration Number
- NCT00228839
- Locations
- 🇺🇸
Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States
Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-08-18
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 112
- Registration Number
- NCT00216177
- Locations
- 🇩🇰
Hvidovre Hospital, Copenhagen, Denmark
🇩🇰Bispebjerg Hospital, Copenhagen, Denmark
🇩🇰Glostrup Hospital, Copenhagen, Denmark
A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT00207675
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.